ArticleLife (Basel, Switzerland)2025
Proteomics Analysis of Plasma Biomarker of Cognitive Frailty in Elders Who Locally Reside in Chiang Mai Province of Thailand.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cognitive frailty in elders has become very common in Thailand society and is extremely difficult to manage in clinical practice due to poor detection and diagnosis. Plasma proteomic studies may be able to provide promising protein markers specific to this condition in order to improve the quality of life in the elderly. The purpose of this study was to differentiate and identify a potential protein marker of cognitive frailty in plasma samples by proteomic approaches. Nine plasma samples from elders with cognitive frailty or non-frailty were pooled and subjected to 2D gel separation. Conventional analysis was performed with the stained gel, and the selected protein spot was identified by liquid chromatography-tandem mass spectrometry coupled to a SCIEX TripleTOF 6600+. It was found that fibrinogen gamma (FGG) chain protein was suggested. FGG was further validated with a commercial ELISA kit using both pooled and individual plasma samples. It was found that both pooled and individual samples showed a significant reduction in FGG levels in elders with cognitive frailty. The results from this study suggest that FGG chain may be a potentially useful plasma biomarker for early detection, diagnosis, and therapeutic applications of cognitive frailty in elders in order to achieve sustainable health in an aging society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.